Dupixent Lawsuit Overview
Dupixent (dupilumab) is a monoclonal antibody biologic drug jointly developed and marketed by Sanofi and Regeneron Pharmaceuticals. First approved by the FDA in 2017 for moderate-to-severe atopic dermatitis (eczema), Dupixent has since received expanded approvals for asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. The drug works by blocking interleukin-4 and interleukin-13 signaling pathways involved in type 2 inflammatory responses. While Dupixent has provided relief for many patients with chronic inflammatory conditions, a growing body of clinical evidence and adverse event reports has revealed significant ocular side effects that plaintiffs allege were inadequately disclosed to patients and healthcare providers.
Clinical trials and post-market surveillance have documented rates of conjunctivitis in Dupixent users significantly higher than placebo groups, with some studies reporting ocular adverse events in up to 30% of atopic dermatitis patients receiving the drug. These eye complications range from mild conjunctivitis to severe keratitis that can threaten vision. Emerging lawsuits allege that Sanofi and Regeneron knew or should have known about the elevated risk of serious eye side effects and failed to provide adequate warnings on the drug label, in prescribing information, and in direct-to-consumer advertising materials.
If you used Dupixent and developed conjunctivitis, keratitis, or other serious eye problems, you may have grounds for a product liability claim. An experienced pharmaceutical injury attorney can evaluate your medical records, treatment history, and the circumstances of your injury to determine whether you may be eligible for compensation covering your medical expenses, lost income, pain and suffering, and other damages.
Dupixent Eye Side Effects and Known Risks
The most commonly reported ocular side effect associated with Dupixent is conjunctivitis, an inflammation of the conjunctiva (the clear membrane covering the white of the eye and inner eyelids). In clinical trials for atopic dermatitis, conjunctivitis occurred in approximately 10-28% of patients receiving Dupixent compared to 2-11% of patients receiving placebo, depending on the study. This significantly elevated rate has been consistently observed across multiple clinical trials and real-world studies, establishing a clear association between Dupixent use and ocular inflammation.
Beyond conjunctivitis, Dupixent has been linked to several other serious eye conditions. Keratitis, an inflammation of the cornea that can cause pain, light sensitivity, and vision impairment, has been reported in a meaningful number of Dupixent users. Some patients have experienced severe or ulcerative keratitis requiring intensive treatment and potentially resulting in permanent vision changes. Other ocular adverse events associated with Dupixent include blepharitis (inflammation of the eyelids), dry eye syndrome, eye pruritus (itching), and limbitis. In rare cases, patients have reported significant visual disturbances or permanent changes to their vision.
Researchers have proposed several mechanisms for Dupixent-associated eye complications. The drug's blockade of IL-13 signaling may disrupt the normal function of conjunctival goblet cells, which produce mucins essential for maintaining tear film stability and ocular surface health. Additionally, the shift in immune balance caused by IL-4/IL-13 inhibition may predispose the ocular surface to inflammatory reactions. Patients with a history of atopic dermatitis may already have an elevated baseline risk of ocular complications, and Dupixent may exacerbate this vulnerability through its mechanism of action.
Who May Qualify for a Dupixent Lawsuit
If you experienced serious eye or vision side effects while taking Dupixent, you may be eligible to pursue a product liability claim against Sanofi and Regeneron. While each case must be evaluated individually, the following criteria are generally considered when determining eligibility:
- 1Dupixent Use
You must have been prescribed and used Dupixent (dupilumab) for any FDA-approved or off-label indication. Medical records, pharmacy records, and insurance claims can help document your Dupixent use history.
- 2Qualifying Side Effect
You must have developed a qualifying ocular side effect such as conjunctivitis, keratitis, blepharitis, severe dry eye, or other vision-related complications during or after Dupixent treatment. Medical documentation from an ophthalmologist or eye specialist strengthens the claim.
- 3Temporal Connection
The eye side effect should have developed during Dupixent treatment or within a reasonable time after use. Many patients report onset within the first few months of treatment, though symptoms can appear at any point during therapy.
- 4Damages Suffered
You must have suffered measurable damages such as medical expenses for eye treatment, lost wages due to inability to work, pain and suffering, or diminished quality of life. Documentation of these damages is important for establishing the value of your claim.
An experienced attorney can review your specific circumstances and advise you on the strength of your potential claim. Most pharmaceutical injury attorneys offer free case evaluations and work on a contingency fee basis, meaning you pay nothing unless your case results in a recovery.
Dupixent Litigation Updates (2026)
Dupixent litigation is still in relatively early stages compared to more established mass tort actions, but the number of claims has been growing steadily. Plaintiffs across multiple jurisdictions have filed product liability lawsuits alleging that Sanofi and Regeneron failed to adequately warn about the risk of serious ocular side effects, including conjunctivitis and keratitis. These claims are based on theories of failure to warn, design defect, and negligence. Attorneys are investigating whether the manufacturers had knowledge of the elevated eye risk from early clinical trial data and chose not to prominently disclose this information.
The FDA has updated the Dupixent prescribing label to include information about conjunctivitis and keratitis, but plaintiffs argue that the warnings remain inadequate and were added too late. Several adverse event reports filed with the FDA Adverse Event Reporting System (FAERS) describe severe ocular complications, including cases requiring hospitalization or resulting in permanent vision changes. As the number of Dupixent prescriptions continues to grow with expanded indications, legal experts anticipate that the litigation will expand as well.
Dupixent generated over $13 billion in global sales in 2024 alone, making it one of the best-selling drugs worldwide. The financial stakes for Sanofi and Regeneron are significant, and early litigation signals suggest that the manufacturers intend to vigorously defend their product. Plaintiffs' attorneys are building cases supported by clinical trial data, expert testimony from ophthalmologists and pharmacologists, and individual patient medical records demonstrating the link between Dupixent use and ocular injury.
How to File a Dupixent Injury Claim
Filing a Dupixent injury claim involves several key steps. First, you should consult with a pharmaceutical injury attorney who has experience handling biologic drug litigation. During your initial consultation, the attorney will review your medical history, Dupixent treatment records, and documentation of your eye side effects to assess the viability of your claim. This consultation is typically free and confidential.
If the attorney determines that you have a viable claim, they will gather additional evidence including your complete medical records, ophthalmology reports, pharmacy records, and any correspondence with your prescribing physician about the side effects you experienced. Expert medical opinions may be obtained to establish the causal connection between Dupixent and your ocular injury. Your attorney will then file a complaint in the appropriate jurisdiction, which may be a state court or a federal court depending on the specifics of your case.
Most Dupixent attorneys handle cases on a contingency fee basis, meaning you pay no upfront costs or hourly fees. The attorney receives a percentage of the compensation recovered only if your case is successful. If no recovery is obtained, you typically owe nothing for legal fees. The statute of limitations for pharmaceutical injury claims varies by state, typically ranging from two to four years from the date of injury or discovery of the injury, so acting promptly is important to preserve your legal rights.
Dupixent FDA Approval and Safety History
Dupixent received its first FDA approval in March 2017 for the treatment of moderate-to-severe atopic dermatitis in adults. Since then, the drug has received multiple supplemental approvals expanding its use to additional conditions and patient populations. In October 2018, Dupixent was approved for moderate-to-severe asthma with an eosinophilic phenotype. Approvals for chronic rhinosinusitis with nasal polyps followed in 2019, eosinophilic esophagitis in 2022, and prurigo nodularis in 2022. The drug has also been approved for adolescent and pediatric populations across several of these indications.
Throughout the approval process and post-market period, ocular adverse events have been a documented concern. Clinical trial data submitted to the FDA showed elevated rates of conjunctivitis in Dupixent-treated patients, particularly in the atopic dermatitis trials. Post-marketing surveillance through FAERS has continued to generate reports of serious ocular complications. The FDA has required label updates to address these risks, though the adequacy and timing of these warnings are central issues in the ongoing litigation. Plaintiffs allege that the manufacturers minimized the severity and frequency of eye side effects in their communications with both healthcare providers and patients.
As of 2026, Dupixent remains on the market and continues to receive regulatory consideration for additional indications. The drug's safety profile is subject to ongoing monitoring by the FDA and international regulatory agencies. Patients who are currently using Dupixent and experiencing eye problems should consult their healthcare provider about their symptoms and discuss whether continuing treatment is appropriate for their individual situation.